Chiesi wins Health Canada priority review for FILSUVEZ in EB

Chiesi Global Rare Diseases has announced that Health Canada has accepted its New Drug Submission (NDS) for FILSUVEZ (birch triterpenes) topical gel under the priority review pathway, targeting the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in patients aged six months and older.

Under Health Canada's priority review process, the submission is subject to an accelerated assessment window of approximately 180 days, compared with the standard 300-day timeline. If approved, FILSUVEZ would become the first therapy specifically authorised by Health Canada for EB-related wound care — a distinction that underscores how underserved this patient population has historically been in Canada.

Trial data and regulatory history

The submission is anchored by the Phase 3 EASE trial, a double-blind, randomised, vehicle-controlled study published in the British Journal of Dermatology in 2023. In that trial, 41.3% of patients in the FILSUVEZ arm achieved complete target wound closure by day 45, compared with 28.9% in the placebo group. Adverse events were broadly comparable across both arms, with wound complications reported in 13.8% of the FILSUVEZ group and 14.9% of the placebo group. A 24-month open-label extension, published in 2025, provided longer-term safety and efficacy data supporting the submission package.

FILSUVEZ already holds regulatory approvals in two major markets: the US Food and Drug Administration granted authorisation in 2023, and the European Commission approved it in 2022. Australia's Therapeutic Goods Administration registered the product in May 2026. Canada, should the priority review proceed to approval, would represent a fourth market for the product.

Mitch Goldman, Senior Vice President for R&D at Chiesi Global Rare Diseases, described the priority review acceptance as "an important regulatory milestone" and noted the company's intent to work with Canadian regulators, patients, and clinicians throughout the process. Erin Hoyos, Executive Director of DEBRA Canada — the country's principal EB patient advocacy organisation — welcomed the development as reflecting "continued progress in the evaluation of potential treatment options."

Market context and competitive landscape

Epidermolysis bullosa affects an estimated 500,000 people worldwide and is characterised by extreme skin fragility, chronic wound burden, and — in severe junctional and dystrophic subtypes — a substantially reduced life expectancy. The condition has historically attracted limited commercial investment given its rarity and the complexity of wound management.

The broader rare skin disease and cell-and-gene therapy space is, however, attracting growing attention. Notably, Krystal Biotech's Vyjuvek (beremagene geperpavec), a gene therapy for dystrophic EB, received FDA approval in 2023 and is under regulatory evaluation in other jurisdictions. The emergence of two mechanistically distinct approved options in the US — a topical botanical and a topical gene therapy — suggests the EB field is entering a more competitive phase, which may benefit Canadian patients through increased regulatory and commercial momentum.

For Chiesi, the priority review acceptance also reflects the company's broader build-out in Canada. Chiesi Canada was established as a formal affiliate of the Parma-headquartered group in January 2026, adding a commercial infrastructure that the company says is intended to support rare disease access across the country. The next key milestone will be Health Canada's decision following the approximately 180-day review window, with the clock presumed to have started upon NDS acceptance.